ACET
What one share of Adicet Bio holds
Pharmaceutical Preparations
We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. We are advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients.
Adicet Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$10.52 |
|---|---|
| Capex (buildings and equipment) | $0.05 |
| Free cash flow | −$9.03 |
| Cash and investments | $3.54 |
| Book value | $12.83 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$8.42 | $0.01 | −$2.75 | — | −$4.76 |
| 2018 | — | −$4.78 | $0.45 | −$9.79 | $0.00 | — |
| 2019 | — | −$13.15 | $0.50 | −$13.54 | $0.00 | −$28.00 |
| 2020 | — | −$5.01 | $0.14 | −$5.81 | $0.00 | — |
| 2021 | — | −$2.00 | $0.42 | −$2.07 | — | $7.63 |
| 2022 | — | −$1.70 | $0.41 | −$1.50 | — | $6.81 |
| 2023 | — | −$3.31 | $0.10 | −$2.28 | — | $3.93 |
| 2024 | — | −$21.33 | $0.20 | −$17.03 | — | $36.16 |
| 2025 | — | −$16.95 | $0.25 | −$14.07 | — | $16.61 |